Skip to content
INO.com
  • Pulse
  • Markets
    • All Markets
    • Futures
    • Stocks
    • Forex
    • World Indices
    • Metals
    • Exchanges
    • Charts
    • Symbol List
    • Extremes
    • Portfolio
  • Analysis
    • Trader's Blog
    • Commentary
    • Stock of the Week
  • MarketClub
    • Join Now
    • Login
    • Top Stocks
    • Top ETFs
    • Top Penny Stocks
    • Top Tech Stocks
    • Top Forex
    • Trend Analysis
    • Videos
    • Market Analysis
    • Email Services
  • Blog
  • Free

Friday Dec 13th, 6:08PM EST

Tag: Medical Coverage

Transformative Combination of HealthEquity and WageWorks

Posted on August 24, 2019August 23, 2019 by Noah Kiedrowski

HealthEquity Inc. (HQY) made a bold move to acquire WageWorks for approximately $2 billion in an all-cash deal. This acquisition will expand HealthEquity’s moat in the Health Savings Account space while providing new revenue verticals in complementary product offerings. This move will expand HealthEquity’s total addressable market as Consumer-Directed Benefits (CDBs) via pre-tax spending accounts such as additional Health Savings Accounts (HSAs), health and dependent care Flexible Spending Accounts (FSAs), health reimbursement accounts (HRA), Commuter Benefit Services, wellness programs, COBRA and other employee benefits are absorbed into its product offerings. This acquisition provides access to a larger client base and access to health brokers that will help drive HealthEquity’s penetration. The majority of HSA clients would prefer to have its CDBs administered by its HSA provider, and more than 50% of HealthEquity’s clients have requested a CDB product. The combination of WageWorks’ leading consumer-directed benefits with HealthEquity’s HSA platform will be highly synergistic and drive growth while expanding the total addressable market in years to come.

HealthEquity’s Unique Positioning

A potential economic slowdown, a trade war with China, tariffs, yield curve inversion, etc., are irrelevant when it comes to HealthEquity. HealthEquity’s business model is such that it stands as an intermediary servicing the secular growth Health Savings Account (HSA) space that’s largely independent of legislative actions, drug pricing, rising insurance costs while not playing any role in the pharmaceutical supply chain from health insurers to end-user pharmacies. The company simply manages funds allocated for medical, dental and vision expenses that are deducted on a pre-tax basis and deposited into a dedicated HSA account. The HSA space has grown in popularity as corporate adoption has allowed access to these plans in conjunction with consumer awareness.
HealthEquity is an intermediary that connects health and wealth to consumers of healthcare. Think of this as a parallel to the credit card companies that only focus on the transactions and not the financial liability of the card user. The banks take on the financial liability of the branded card (i.e., Visa or Mastercard) and merely facilitate the financial transaction. HealthEquity has partnerships with over 45,000 employers and 141 health, retirement, and other benefit plan providers nationwide. HealthEquity is the custodian of $8.3 billion in assets for 4.1 million HSA members nationwide. The company continues to post quarter after double-digit quarter growth in revenue and EPS without any debt on the balance sheet. Recently, the company released its Q1 2020 results Continue reading "Transformative Combination of HealthEquity and WageWorks" →

Posted in INO.com ContributorsTagged Affordable Health Care Act Flexible Savings Account (FSA) Health Plans Health Savings Account (HSA) HealthEquity Inc. (NASDAQ:HQY) High Deductible Health Plans (HDHPs) HSA Assets Medical Coverage Medical Plan Premiums noah kiedrowski Retirement Planning Tax Break traditional IRA WageWorks

HealthEquity: Incorrectly Correlated To Healthcare Downturn

Posted on June 22, 2019June 20, 2019 by Noah Kiedrowski

HealthEquity Inc. (HQY) has witnessed several volatile moves of significant magnitude over the past few months with sell-offs highly correlated to the overall healthcare sector. Despite the company’s fundamentals, growth narrative, financial profile, and addressable market remaining strong and positive, the stock has underperformed over the past few months. Historically, HealthEquity’s valuation has been rich, so it’s no surprise that the stock has traded off with the broader market downturns, which disproportionally impact growth stocks with high price-to-earnings multiples. HealthEquity has traded in a 52-week range between $101 and $50 and currently trades at the $70 level after posting its most recent earnings. The company continues to post quarter after double-digit quarter growth in revenue and EPS without any debt on the balance sheet. I feel that the stock is incorrectly lumped into the broader healthcare cohort due to its business model and independence from healthcare insurers, the pharmaceutical supply chain, and drug manufacturers. For long-term investors, HealthEquity presents a compelling picture of growth with a large addressable market moving forward.

Incorrect Correlation to Healthcare

HealthEquity’s business model is such that it stands as an intermediary servicing the secular growth Health Savings Account (HSA) space that’s largely independent of legislative actions, drug pricing, rising insurance costs while not playing any role in the pharmaceutical supply chain from health insurers to end user pharmacies. The company simply manages funds allocated for medical, dental, and vision expenses that are deducted on a pre-tax basis and deposited into a dedicated HSA account. The HSA space has grown in popularity as corporate adoption has allowed access to these plans in conjunction with consumer awareness.
Many of the healthcare related stocks have lost significant portions of their respective market capitalization over the past year. Large-cap stocks such as CVS Health (CVS), Walgreens (WBA), McKesson (MCK) and Cardinal Health (CAH) have been some of the worst performing stocks. These stocks have been in secular decline due to the confluence of legislative threats, drug pricing pressures, and pro-single payer healthcare by top Democratic officials. HealthEquity is in a unique position that circumvents many issues that have plagued these stocks. The company is here to stay regardless of the aforementioned hot button issues. Continue reading "HealthEquity: Incorrectly Correlated To Healthcare Downturn" →

Posted in INO.com ContributorsTagged Affordable Health Care Act Flexible Savings Account (FSA) Health Plans Health Savings Account (HSA) HealthEquity Inc. (NASDAQ:HQY) High Deductible Health Plans (HDHPs) HSA Assets Medical Coverage Medical Plan Premiums noah kiedrowski Retirement Planning Tax Break traditional IRA

HealthEquity - Compelling Buy Heading Into Q4 Earnings

Posted on March 2, 2019March 1, 2019 by Noah Kiedrowski

HealthEquity Inc. (HQY) was not immune to the market wide sell-off in equities during the fourth quarter of 2018 which disproportionally impacted growth stocks with high price-to-earnings multiples. The market quickly lost its appetite for these richly valued high-growth stocks with steep valuations. Health Equity’s rich valuation became a concern to me during the fourth quarter as its growth albeit double-digits, did not justify its sky-high valuation. This concern prompted me to write a piece discussing this concern and warned that the “current valuation is rich in an already frothy market thus caution at these levels is wise” prior to the stock selling off from $101 to $47 shedding 53% of its market value during the fourth quarter of 2018. The company continues to post quarter after quarter of double-digit growth in revenue and EPS without any debt on the balance sheet thus has been rewarded with a rich valuation as a function of its impressive growth and total addressable market. This high price-to-earnings multiple came under fire as the market moved into a risk-averse environment in the fourth quarter. As high-flying equities came down in the broader market sell-off, Health Equity lost over half of its market capitalization and erased all of its gains in 2018. Now that the market correction has passed and the company continues to post great quarterly growth along with enhancing its growth profile, the valuation is now compelling moving into its Q4 earnings and the stock is still well off its highs for a long-term investment.

Addressable Market and Market Position

On the fundamental level, the company is an intermediary servicing the secular growth Health Savings Account (HSA) space that’s largely independent of legislative actions, drug pricing, rising insurance costs while not playing any role in the pharmaceutical supply chain. The company manages funds allocated for medical, dental and vision expenses that are deducted on a pre-tax basis and deposited into a dedicated HSA account. The HSA space has grown in popularity as corporate adoption has allowed access to these plans in conjunction with consumer awareness. Continue reading "HealthEquity - Compelling Buy Heading Into Q4 Earnings" →

Posted in INO.com ContributorsTagged Affordable Health Care Act Flexible Savings Account (FSA) Health Plans Health Savings Account (HSA) HealthEquity Inc. (NASDAQ:HQY) High Deductible Health Plans (HDHPs) HSA Assets Medical Coverage Medical Plan Premiums noah kiedrowski Retirement Planning Tax Break traditional IRA

HealthEquity Inc. - Rich Valuation Concerns?

Posted on December 7, 2018 by Noah Kiedrowski

The market-wide sell-off in equities during the fourth quarter has disproportionally impacted growth stocks that possess high price-to-earnings multiples translating into rich valuations. The market appears to have lost its appetite for the high growth and steep valuation equities that had huge upward moves throughout this record-setting bull market. HealthEquity Inc. (HQY) continues to post quarter after double-digit quarter growth in revenue and EPS and has been rewarded with a rich valuation as a function of its impressive growth. This high price-to-earnings multiple may be in jeopardy as the market moves into a risk-averse environment. As high-flying equities come down in the broader market sell-off, Health Equity may come down as a result and erase some of its monster gains that were witnessed in 2018. To be clear, Health Equity is an intermediary servicing the secular growth Health Savings Account (HSA) space that’s largely independent of legislative actions, drug pricing, rising insurance costs and not playing any role in the pharmaceutical supply chain. HealthEquity manages funds allocated for medical, dental and vision expenses that are deducted on a pre-tax basis and deposited into a dedicated HSA account. The company blew out the numbers when it reported its Q3 FY19 results and beat on both the top and bottom line.

HealthEquity manages $7.1 billion in assets across 3.7 million accounts against a potential market maturity of $1 trillion in assets across 50-60 million accounts. The durability of this growth has a long runway due to the secular growth in the HSA market. The company is sitting on largely untapped revenue sources where the vast majority of account holders have yet to invest any HSA money in investment offerings. Expanding margins for greater profitability is also unfolding as the older the account, the greater the gross margins. HealthEquity is currently sitting on a healthy balance sheet with $330 million in cash and cash equivalents with no debt. The company is posting accelerating revenue, cash flow, margin expansion and income growth with a strong balance sheet. I feel that HealthEquity will continue to post strong growth as it services the double-digit HSA growth market and manages more assets, accounts, and investments within these accounts. HealthEquity may be a great long-term investment in the healthcare space that’s independent of the health insurances, pharmaceutical supply chain companies, drug makers or pharmacies. Previously, I warned that the “current valuation is rich in an already frothy market thus caution at these levels is wise” and now it appears this heeding was responsible as the stock has sold off from $101 to $74 shedding 26% of its market value during the fourth quarter. Health Equity looks compelling after this healthy correction as the long-term narrative remains intact. Continue reading "HealthEquity Inc. - Rich Valuation Concerns?" →

Posted in INO.com ContributorsTagged Affordable Health Care Act Flexible Savings Account (FSA) Health Plans Health Savings Account (HSA) HealthEquity Inc. (NASDAQ:HQY) High Deductible Health Plans (HDHPs) HSA Assets Medical Coverage Medical Plan Premiums noah kiedrowski Retirement Planning Tax Break traditional IRA

HealthEquity Inc. - Roaring Through $100

Posted on September 15, 2018September 14, 2018 by Noah Kiedrowski

I’ve written several articles highlighting HealthEquity Inc. (HQY) since the sub $40 range as a great play on the secular growth in the Health Savings Account (HSA) space that’s mostly independent of legislative actions, the drug pricing debate or rising insurance costs. HealthEquity is not an insurance company thus does not possess any liability for coverage in any capacity nor does the company play any role in the pharmaceutical supply chain. HealthEquity is at the center of a healthcare paradigm shift where consumers are taking control of their healthcare dollars via leveraging HSAs. HealthEquity manages funds allocated for medical, dental and vision expenses that are deducted on a pre-tax basis and deposited into a dedicated HSA account. The company blew out the numbers when it reported its Q2 FY19 results with the stock following suit breaking out above $95 per share to an all-time high of $98 and looking to break through $100.

HealthEquity manages $7.0 billion in assets across 3.6 million accounts against a potential market maturity of $1 trillion in assets across 50-60 million accounts. The durability of this growth has a long runway due to the secular growth in the HSA market. The company is sitting on largely untapped revenue sources where the vast majority of account holders have yet to invest any HSA money in investment offerings. Expanding margins for greater profitability is also unfolding as the older the account, the greater the gross margins observed. HealthEquity is currently sitting on a healthy balance sheet with ~$303 million in cash and cash equivalents with zero debt. The company is posting accelerating revenue, cash flow, margin expansion and income growth with a strong balance sheet. I feel that HealthEquity will continue to post strong growth as it services the double-digit HSA growth market and manages more assets, accounts, and investments within these accounts. HealthEquity may be a great long-term investment in the healthcare space that’s independent of the health insurances, pharmaceutical supply chain companies, drug makers or pharmacies. The current valuation is rich in an already frothy market thus caution at these levels is wise.

HealthEquity’s FY19 Q1 Earnings and Analyst Sentiment

Q1 FY19 earnings delivered another double-digit growth story across the board with revenue coming in at $71.1 million, an increase of 25% year-over-year. Net income came in at $22.5 million, an increase of 33% year-over-year. Total HSA members came in at 3.6 million, an increase of 23% compared to Q2 FY18. Total custodial assets were $7.0 billion, an increase of 31% compared to year-over-year. Continue reading "HealthEquity Inc. - Roaring Through $100" →

Posted in INO.com ContributorsTagged Affordable Health Care Act Flexible Savings Account (FSA) Health Plans Health Savings Account (HSA) HealthEquity Inc. (NASDAQ:HQY) High Deductible Health Plans (HDHPs) HSA Assets Medical Coverage Medical Plan Premiums noah kiedrowski Retirement Planning Tax Break traditional IRA

Posts navigation

Older posts

Trader’s Blog Alerts

Enter your e-mail address here to receive an alert for a new post or video:

Search Trader’s Blog

Recent Posts

  • Stocks Falter After Phase-One Trade Deal
  • World Oil Supply And Price Outlook, December 2019
  • 2 Out Of 3 Americans Are Involved In this Industry
  • Good News Is… Good News
  • Gold & Silver: Last Drop Ahead Of Santa Claus Rally?

Market Reports

  • Gold
  • S&P500
  • Dow
  • Nasdaq
  • Crude Oil

Trader Comments

  • veesh on Gold & Silver Stocks Belie COT Caution
  • Rasesh Shukla - India on Is A Real Estate Crash Coming?
  • Lee Yoder on Gold & Silver Stocks Belie COT Caution
  • pater eusebius tenebrarum on Trump Sinks Stocks With Trade Comments
  • Howard Whang on Is A Real Estate Crash Coming?

Categories

  • General
  • INO Cares
  • INO.com Contributors
  • MarketClub Options
  • MarketClub Techniques, Tips & Talk
  • Member Success Stories
  • Trading Videos

Blogroll

  • 4 Futures Newsletter
  • Add Your Blog Here
  • Biiwii TA and Commentary
  • Cannabis Stock Trades
  • Crude Oil Trader
  • ETF Daily News
  • Feed The Bull
  • Learn Options Trading
  • Online Stock Trading Guide
  • Options Trading Mastery
  • Scott's Investments
  • Stock Gumshoe
  • Traders Day Trading
  • Vantage Point Trading
  • VantagePoint Trading Software
Find INO.com on Facebook Follow MarketClub on Twitter Find MarketClub on YouTube
  • Pulse
  • Markets
  • MarketClub
  • Blog
  • Advertising
  • Help
  • Contact Us
  • Usage Agreement
  • Privacy Policy

© Copyright INO.com, Inc. All Rights Reserved.